Articles from Univo IRB

Univo IRB today announced a partnership with The Patient View to provide essential patient insights that will improve clinical trial participation and retention for sponsors and CROs. By engaging with patient populations similar to those targeted for enrollment, the partnership helps highlight patient burden and provides practical and actionable strategies that support successful trial execution.

Univo IRB, today’s fastest-growing central institutional review board (IRB), announced it has successfully completed a routine inspection by the U.S. Food and Drug Administration (FDA) with no findings. The outcome exemplifies Univo IRB’s unwavering commitment to protecting research participants and upholding the highest standards of ethical and regulatory oversight in clinical research.

Univo IRB, today’s fastest growing central IRB, and a pioneering leader in ethics review and research oversight, announced a major milestone in the evolution of institutional review board (IRB) operations with the official launch of AI workflows and continuous features available through their revolutionary IRB platform, OneVerse. The platform seamlessly integrates artificial intelligence (AI) into IRB workflows, allowing for unparalleled speed and quality of administrative tasks, which creates time and space for human oversight, interactions, and a top-rated customer experience.

Univo IRB, a leader in ethical review and oversight for clinical research, is proud to announce the launch of its Canadian research ethics board (REB) review services. This new offering is designed to support clinical trials conducted across North America, ensuring that reviews exceed the industry’s highest standards of ethical integrity and regulatory compliance.

Univo IRB, a next generation institutional review board (IRB), announced the launch of OneVerse™ — the industry’s first purpose-built, electronic platform that modernizes the IRB experience. OneVerse is designed around user experience and transparency, facilitating seamless study submission, secure document sharing, and direct communication across all research study stakeholders.

Univo IRB, a next generation institutional review board (IRB) backed by QHP Capital, today announced Julie Blasingim has been promoted to CEO by Univo’s board of directors. As CEO, Blasingim will drive Univo IRB’s strategic growth and innovation, bringing a modern iteration of IRB solutions to unify patients and research, and support today’s clinical trials.

Today, Univo IRB was announced as the new company name for Principal IRB. Univo IRB is a next generation institutional review board (IRB) recently acquired by QHP Capital, an investment manager exclusively focused on building and supporting tech-enabled life sciences and pharma services companies. Univo IRB is focused on full-scale IRB services, bringing decades of IRB and clinical operations experience to support today’s clinical trials.